Advances in reproductive health research have greatly expanded the capabilities of cytogenetics testing in recent years. The emergence of microarray analysis has provided us with insights into genetic risk factors and disorders which are essential to the understanding of reproductive health.
Thermo Fisher Scientific is dedicated to building strong partnerships with cytogenetics laboratories by offering reliable sample to insights microarray research solutions. Our onboarding support is committed to helping you all the way-from starting up to ramping up.
Partner with us to drive path-breaking reproductive health research.
Your trusted partners from sample to insights
Chromosomal microarray (CMA) is a widely used genetic analysis tool, recommended by American College of Medical Genetics (ACMG) as a first-tier test for postnatal research of unexplained developmental delay, intellectual disability, congenital anomalies, and autism spectrum disorder. The American College of Obstetricians and Gynecologists (ACOG) proposes that CMA be used as the primary prenatal genetic analysis method of choice. This is based on the major advantage of CMA over standard karyotyping in terms of increased discovery yield. CMA is used to study more genetic abnormalities than traditional cytogenetic methods such as karyotyping. CMA is an ideal platform for CNV analysis and molecular cytogenetic research.
Thermo Fisher Scientific offers microarray solutions with robust workflows that make it easy to obtain consistent and high-quality results. Our complete microarray platform for prenatal and postnatal research, the CytoScan Cytogenetics Suite, includes hybrid-SNP arrays, automated and manual target preparation options, fully kitted reagents, the GeneChip System 3000 instrument for array processing, and Chromosome Analysis Suite (ChAS) software for data interpretation and reporting. These tools support labs to generate accurate, high-quality data and maximize operational time.
For Research Use Only. Not for use in diagnostic procedures.